CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies
In multiple myeloma (MM), the anti-CD38 monoclonal antibody Daratumumab has become essential in the therapeutic arsenal, although very few predictive factors of response to Daratumumab have been identified in clinical studies. We have prospectively collected biological data from 97 patients treated...
保存先:
| 主要な著者: | , , , , , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis Group
2025-12-01
|
| シリーズ: | OncoImmunology |
| 主題: | |
| オンライン･アクセス: | https://www.tandfonline.com/doi/10.1080/2162402X.2025.2532226 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|